Home › Companies › JBIO

Jade Biosciences

Market cap $1.07B 69.2M shares (10-Q, Nov 6, 2026) × $15.40 close Nov 17, 2026

Most recent annual filing: 2026-03-06

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Parade warrant corporate updateDec 31, 2026Parade warrant corporate update, Dec 31, 2026, routine
  2. JADE201 Ph1 interim2027JADE201 Ph1 interim, 2027, material
  3. JADE301 HV Ph1 interim2H 2027JADE301 HV Ph1 interim, 2H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Capital (as filed)

Cash
$80.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$395M Sep 30, 2026
Operating cash flow
−$28.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$476M cash, runway Q4 2028 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (12)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (12 calls)

Every verdict Biotech Distilled has published on Jade Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Jade Biosciences (JBIO) - Scientific Deep Dive for JADE101 and Pipeline Products Jade's entire valuation rests on unproven monkey-to-human translation; wait for Q2 2026 Phase 1 human PK/PD data before buying.
  2. Watch UPDATE: Jade Biosciences (JBIO) - The $200M ATM Lands 6 Weeks Before the Monkey-to-Human Verdict Watch List maintained; $200M ATM adds dilution overhang to the post-readout bull case but does not change the binary — wait for Q2 human PK/PD data before sizing a position.
  3. Watch UPDATE: Jade Biosciences (JBIO) - Two First-Patient-Dosed PRs Before the Monkey-to-Human Verdict Watch List maintained; pre-readout Phase 2 enrollment amplifies the bear case on a miss but does not change the binary — still wait for Q2 HV readout before sizing.
  4. Watch UPDATE: Jade Biosciences (JBIO) - The Binary Has a Date: Monday, 8:00 a.m. ET Watch List maintained with three trading days to the binary; positions entered before Monday are a pure binary gamble — wait for the readout before sizing.
  5. Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - The Monkey Translated. The Stock Dropped 11.6% Anyway. All four binary risks (translation failure, PK collapse, ADAs, safety signal) retired on clean Phase 1 data; the 11.6% drop is mechanical ATM overhang, not fundamental, making the $15–18 zone asymmetric for patient capital.
  6. Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - The Dilution I Telegraphed, Just Not Through the Door I Expected Speculative Buy maintained; marketed underwritten deal concentrates dilution into a single event rather than an ATM drip, and the likely $15–17 clearing range lands squarely in the asymmetric entry zone flagged on June 1.
  7. Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - The Deal Priced at the Floor of My Range Speculative Buy maintained; deal cleared at $15.00 (14.7% discount) at the floor of the asymmetric entry zone, concentrating dilution into one event and leaving a de-risked Phase 3-ready asset with ~$4.70/share cash backing.
  8. Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - The Wildcard Option Got Exercised Speculative Buy maintained; JADE301 formally licensed from Paragon deepens the pipeline to three programs, but the +22.9% rally has moved the stock out of the asymmetric $15–18 entry zone and the ATM lockup expires imminently.
  9. Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - The Wildcard Has a Name: Interferon-Beta Speculative Buy maintained; JADE301 unmasked as anti-IFN-β for dermatomyositis with Q4 2026 Phase 1 pulled forward, balance sheet fortified to $461M through Q4 2028, though margin of safety is thinner than in early June.
  10. Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - The Wildcard's Monkey Data, and a Stock Below the Deal Price Speculative Buy maintained below the $15 deal price; JADE301 monkey data is competent and on-template, JADE101 science unchanged, but broken deal floor creates overhead supply and makes the ATM a costlier tool — patient capital may wait for Q3 10-Q before sizing up.
  11. Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - EVERGREEN Arrives Early Speculative Buy maintained; EVERGREEN Phase 3 pulled to Q4 2026 defuses one of the two stated AVOID triggers, stock back above the $15 deal price, but Q3 10-Q ATM activity remains the key near-term test.
  12. Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - The ATM Didn't Sell the Dip Speculative Buy maintained; Q3 10-Q confirms ATM sales averaged ~$20.80 (not the $14s), $475.7M cash with runway into Q4 2028 survives EVERGREEN pull-forward, and both stated AVOID triggers are now defused — what remains is binary science in Q2 2027.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (5 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (44)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 26, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

24 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)